PL4055021T3 - Heterocykliczne związki hamujące RIP1 - Google Patents
Heterocykliczne związki hamujące RIP1Info
- Publication number
- PL4055021T3 PL4055021T3 PL20816790.8T PL20816790T PL4055021T3 PL 4055021 T3 PL4055021 T3 PL 4055021T3 PL 20816790 T PL20816790 T PL 20816790T PL 4055021 T3 PL4055021 T3 PL 4055021T3
- Authority
- PL
- Poland
- Prior art keywords
- heterocyclic compounds
- compounds inhibiting
- inhibiting rip1
- rip1
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932404P | 2019-11-07 | 2019-11-07 | |
| US202063001016P | 2020-03-27 | 2020-03-27 | |
| US202063004290P | 2020-04-02 | 2020-04-02 | |
| US202063004301P | 2020-04-02 | 2020-04-02 | |
| US202063004319P | 2020-04-02 | 2020-04-02 | |
| PCT/US2020/059348 WO2021092336A1 (en) | 2019-11-07 | 2020-11-06 | Heterocyclic rip1 inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4055021T3 true PL4055021T3 (pl) | 2026-02-16 |
Family
ID=73646543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20816790.8T PL4055021T3 (pl) | 2019-11-07 | 2020-11-06 | Heterocykliczne związki hamujące RIP1 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11578078B2 (pl) |
| EP (1) | EP4055021B1 (pl) |
| JP (1) | JP7395730B2 (pl) |
| KR (2) | KR20250095767A (pl) |
| CN (1) | CN115298184B (pl) |
| AU (1) | AU2020378407B2 (pl) |
| CA (1) | CA3156594A1 (pl) |
| DK (1) | DK4055021T3 (pl) |
| ES (1) | ES3055608T3 (pl) |
| FI (1) | FI4055021T3 (pl) |
| HR (1) | HRP20251589T1 (pl) |
| IL (1) | IL292536B1 (pl) |
| LT (1) | LT4055021T (pl) |
| MX (1) | MX2022005509A (pl) |
| PL (1) | PL4055021T3 (pl) |
| PT (1) | PT4055021T (pl) |
| RS (1) | RS67546B1 (pl) |
| SI (1) | SI4055021T1 (pl) |
| TW (1) | TWI897895B (pl) |
| WO (1) | WO2021092336A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3788045T2 (ro) * | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| CN114989156B (zh) * | 2021-05-19 | 2024-07-05 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| TWI838849B (zh) * | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| EP4422621A4 (en) * | 2021-10-27 | 2025-08-27 | Merck Sharp & Dohme Llc | SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF |
| US20250197390A1 (en) * | 2022-03-16 | 2025-06-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused heterocyclic compound, and preparation method therefor and medical use thereof |
| CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| DK0431519T3 (da) | 1989-12-04 | 1994-07-04 | Searle & Co | System til transdermal indgivelse af albuterol |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| BR112017017411A2 (pt) | 2015-02-13 | 2018-04-03 | Glaxosmithkline Ip Dev Ltd | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| ES2885474T3 (es) | 2015-10-13 | 2021-12-13 | Inst Nat Sante Rech Med | Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular |
| AU2016340527B2 (en) | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MD3788045T2 (ro) * | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| TW202019913A (zh) | 2018-06-26 | 2020-06-01 | 中國科學院上海有機化學研究所 | 細胞壞死抑制劑及其製備方法和用途 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7493586B2 (ja) * | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
-
2020
- 2020-11-06 SI SI202030696T patent/SI4055021T1/sl unknown
- 2020-11-06 KR KR1020257020567A patent/KR20250095767A/ko active Pending
- 2020-11-06 EP EP20816790.8A patent/EP4055021B1/en active Active
- 2020-11-06 ES ES20816790T patent/ES3055608T3/es active Active
- 2020-11-06 KR KR1020227015301A patent/KR102824962B1/ko active Active
- 2020-11-06 WO PCT/US2020/059348 patent/WO2021092336A1/en not_active Ceased
- 2020-11-06 MX MX2022005509A patent/MX2022005509A/es unknown
- 2020-11-06 JP JP2022526157A patent/JP7395730B2/ja active Active
- 2020-11-06 PT PT208167908T patent/PT4055021T/pt unknown
- 2020-11-06 US US17/091,270 patent/US11578078B2/en active Active
- 2020-11-06 CA CA3156594A patent/CA3156594A1/en active Pending
- 2020-11-06 RS RS20251291A patent/RS67546B1/sr unknown
- 2020-11-06 PL PL20816790.8T patent/PL4055021T3/pl unknown
- 2020-11-06 LT LTEPPCT/US2020/059348T patent/LT4055021T/lt unknown
- 2020-11-06 FI FIEP20816790.8T patent/FI4055021T3/fi active
- 2020-11-06 CN CN202080092168.3A patent/CN115298184B/zh active Active
- 2020-11-06 TW TW109138824A patent/TWI897895B/zh active
- 2020-11-06 AU AU2020378407A patent/AU2020378407B2/en active Active
- 2020-11-06 DK DK20816790.8T patent/DK4055021T3/da active
- 2020-11-06 HR HRP20251589TT patent/HRP20251589T1/hr unknown
-
2022
- 2022-04-26 IL IL292536A patent/IL292536B1/en unknown
- 2022-12-16 US US18/067,384 patent/US20230143161A1/en not_active Abandoned
-
2024
- 2024-09-27 US US18/899,350 patent/US20250092057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115298184A (zh) | 2022-11-04 |
| SI4055021T1 (sl) | 2026-02-27 |
| AU2020378407A1 (en) | 2022-06-02 |
| IL292536B1 (en) | 2026-03-01 |
| MX2022005509A (es) | 2022-10-18 |
| DK4055021T3 (da) | 2025-12-15 |
| RS67546B1 (sr) | 2026-01-30 |
| TWI897895B (zh) | 2025-09-21 |
| CN115298184B (zh) | 2025-01-28 |
| PT4055021T (pt) | 2025-12-17 |
| JP2023501399A (ja) | 2023-01-18 |
| CA3156594A1 (en) | 2021-05-14 |
| KR20220079919A (ko) | 2022-06-14 |
| EP4055021B1 (en) | 2025-10-08 |
| US20210139494A1 (en) | 2021-05-13 |
| FI4055021T3 (fi) | 2025-12-16 |
| JP7395730B2 (ja) | 2023-12-11 |
| ES3055608T3 (en) | 2026-02-13 |
| KR20250095767A (ko) | 2025-06-26 |
| LT4055021T (lt) | 2026-01-12 |
| KR102824962B1 (ko) | 2025-06-26 |
| US20250092057A1 (en) | 2025-03-20 |
| US20230143161A1 (en) | 2023-05-11 |
| WO2021092336A1 (en) | 2021-05-14 |
| US11578078B2 (en) | 2023-02-14 |
| IL292536A (en) | 2022-06-01 |
| EP4055021A1 (en) | 2022-09-14 |
| TW202132307A (zh) | 2021-09-01 |
| AU2020378407B2 (en) | 2024-02-01 |
| HRP20251589T1 (hr) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4055021T3 (pl) | Heterocykliczne związki hamujące RIP1 | |
| IL290779A (en) | Heterocyclic rip1 kinase inhibitors | |
| IL292753A (en) | Compounds | |
| IL283333A (en) | New heterocyclic compounds | |
| IL286833A (en) | Compositions containing brazzein | |
| DK4083038T3 (da) | Pyridazinylthiazolcarboxamidforbindelse | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| IL280821A (en) | Heterocycline compound | |
| EP3919055A4 (en) | HETEROCYCLIC COMPOUND | |
| EP4066893A4 (en) | HETEROCYCLIC COMPOUND | |
| IL279977A (en) | Anthelminthic heterocyclic compounds | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| ZA202104402B (en) | Heterocyclic compound | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| IL288987A (en) | New heterocyclic compounds | |
| DK3782986T3 (da) | Heterocyklisk forbindelse | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| EP3883918A4 (en) | RIP1 INHIBITORS | |
| IL285046A (en) | Anti-apicomplexan compositions | |
| GB201806488D0 (en) | Heterocyclic TADF compounds | |
| IL277340A (en) | The orthocyclic compound | |
| EP4046688A4 (en) | HETEROCYCLIC COMPOUND | |
| EP4005638A4 (en) | Heterocyclic compound | |
| GB201808580D0 (en) | Heterocyclic compounds |